We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Perrigo to Report Q2 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
PRGO will report Q2 earnings on Aug. 6, with estimates set at $1.08 billion in sales and $0.59 EPS.
Sales may be pressured by exited businesses, product cuts and adverse currency shifts.
Investors await updates on PRGO's Kairos deal and macroeconomic impact expectations.
Perrigo Company plc (PRGO - Free Report) is scheduled to report second-quarter 2025 earnings on Aug. 6, before the opening bell. The company’s earnings beat estimates by 7.14% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $1.08 billion and 59 cents per share, respectively.
Factors Likely to Shape PRGO’s Upcoming Results
Perrigo reports its results under two segments — Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).
We expect second-quarter sales to have been impacted on account of exited businesses and product lines and unfavorable currency movements.
The Zacks Consensus Estimate and our model estimate for CSCA sales are pegged at $636 million and $641 million, respectively. The Zacks Consensus Estimate and our model estimate for sales in the CSCI segment are pegged at $445 million and $439 million, respectively.
We expect investors to seek updates from Perrigo on the progress of the deal signed with KKR-backed Kairos Bidco AB to sell its Dermacosmetics-branded business for up to €327 million. The company is also expected to provide an update on the expected impact of macroeconomic pressures in the upcoming quarters.
PRGO’s Earnings Surprise History
The company’s earnings performance has been decent over the trailing four quarters. Its earnings beat estimates in three of the last four quarters and missed the mark on one occasion, delivering an average surprise of 4.36%.
Perrigo’s shares have outperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
What Our Model Predicts for PRGO Stock
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is not the case here, as you will see below. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Here are some biotech stocks that have the right combination of elements to beat on earnings this reporting cycle:
BioNTech (BNTX - Free Report) currently has an Earnings ESP of +40.15% and a Zacks Rank of 1.
BNTX stock has lost 2% year to date. It beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 56.47%. BioNTech intends to report second-quarter earnings on Aug. 4, before the opening bell.
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank of 2 at present.
Shares of EXAS have lost 15% year to date. It beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is expected to report second-quarter results on Aug. 6, after market close.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Perrigo to Report Q2 Earnings: What's in Store for the Stock?
Key Takeaways
Perrigo Company plc (PRGO - Free Report) is scheduled to report second-quarter 2025 earnings on Aug. 6, before the opening bell. The company’s earnings beat estimates by 7.14% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $1.08 billion and 59 cents per share, respectively.
Factors Likely to Shape PRGO’s Upcoming Results
Perrigo reports its results under two segments — Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).
We expect second-quarter sales to have been impacted on account of exited businesses and product lines and unfavorable currency movements.
The Zacks Consensus Estimate and our model estimate for CSCA sales are pegged at $636 million and $641 million, respectively. The Zacks Consensus Estimate and our model estimate for sales in the CSCI segment are pegged at $445 million and $439 million, respectively.
We expect investors to seek updates from Perrigo on the progress of the deal signed with KKR-backed Kairos Bidco AB to sell its Dermacosmetics-branded business for up to €327 million. The company is also expected to provide an update on the expected impact of macroeconomic pressures in the upcoming quarters.
PRGO’s Earnings Surprise History
The company’s earnings performance has been decent over the trailing four quarters. Its earnings beat estimates in three of the last four quarters and missed the mark on one occasion, delivering an average surprise of 4.36%.
Perrigo Company plc Price and EPS Surprise
Perrigo Company plc price-eps-surprise | Perrigo Company plc Quote
Perrigo’s shares have outperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
What Our Model Predicts for PRGO Stock
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is not the case here, as you will see below. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Perrigo has an Earnings ESP of 0.00% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks With the Favorable Combination
Here are some biotech stocks that have the right combination of elements to beat on earnings this reporting cycle:
BioNTech (BNTX - Free Report) currently has an Earnings ESP of +40.15% and a Zacks Rank of 1.
BNTX stock has lost 2% year to date. It beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 56.47%. BioNTech intends to report second-quarter earnings on Aug. 4, before the opening bell.
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank of 2 at present.
Shares of EXAS have lost 15% year to date. It beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is expected to report second-quarter results on Aug. 6, after market close.